BACKGROUND AND PURPOSE: The Interventional Management of Stroke (IMS)-III trial randomized patients with acute ischemic stroke tointravenous tissue-type plasminogen activator (tPA) plus endovascular therapy versus intravenous tPA therapy alone within 3 hours from symptom onset. A predefined secondary hypothesis was that subjects with significant early ischemic change on the baseline scan would not respond to endovascular therapy. METHODS: The primary outcome was 90-day modified Rankin Scale score 0 to 2. The baseline and follow-up computed tomographic (CT) scan images were reviewed centrally and blinded to any clinical information. We assessed whether the baseline Alberta Stroke Program Early CT Score (ASPECTS) predicted outcome and interacted with study treatment. We analyzed subgroups defined by time from onset to intravenous tPA initiation and baseline occlusion status at a prespecified α=0.01. RESULTS: Baseline demographic and clinical characteristics of 656 randomized patients were similar between subjects with a baseline ASPECTS 8 to 10 (58% of the study sample) versus 0 to 7. Subjects with ASPECTS 8 to 10 were almost twice as likely (relative risk, 1.8; 99% confidence interval, 1.4-2.4) to achieve a favorable outcome. There was insufficient evidence of a treatment-by-ASPECTS interaction. In those treated with onset to intravenous tPA <120 minutes, in CT angiography-proven internal carotid artery or middle cerebral artery occlusion, and in both, results were similar. The probability of achieving recanalization (arterial occlusion lesion, 2-3) of the primary arterial occlusive lesion (relative risk, 1.3; 99% confidence interval, 1.0-1.8) or achieving thrombolysis in cerebral ischemia score 2b/3 reperfusion (relative risk 2.0; 99% confidence interval, 1.2-3.2) was higher among subjects with higher ASPECTS. CONCLUSIONS: ASPECTS is a strong predictor of outcome and a predictor of reperfusion. ASPECTS did not identify a subpopulation of subjects that particularly benefitted from endovascular therapy immediately after routine intravenous tPA. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
RCT Entities:
BACKGROUND AND PURPOSE: The Interventional Management of Stroke (IMS)-III trial randomized patients with acute ischemic stroke to intravenous tissue-type plasminogen activator (tPA) plus endovascular therapy versus intravenous tPA therapy alone within 3 hours from symptom onset. A predefined secondary hypothesis was that subjects with significant early ischemic change on the baseline scan would not respond to endovascular therapy. METHODS: The primary outcome was 90-day modified Rankin Scale score 0 to 2. The baseline and follow-up computed tomographic (CT) scan images were reviewed centrally and blinded to any clinical information. We assessed whether the baseline Alberta Stroke Program Early CT Score (ASPECTS) predicted outcome and interacted with study treatment. We analyzed subgroups defined by time from onset to intravenous tPA initiation and baseline occlusion status at a prespecified α=0.01. RESULTS: Baseline demographic and clinical characteristics of 656 randomized patients were similar between subjects with a baseline ASPECTS 8 to 10 (58% of the study sample) versus 0 to 7. Subjects with ASPECTS 8 to 10 were almost twice as likely (relative risk, 1.8; 99% confidence interval, 1.4-2.4) to achieve a favorable outcome. There was insufficient evidence of a treatment-by-ASPECTS interaction. In those treated with onset to intravenous tPA <120 minutes, in CT angiography-proven internal carotid artery or middle cerebral artery occlusion, and in both, results were similar. The probability of achieving recanalization (arterial occlusion lesion, 2-3) of the primary arterial occlusive lesion (relative risk, 1.3; 99% confidence interval, 1.0-1.8) or achieving thrombolysis in cerebral ischemia score 2b/3 reperfusion (relative risk 2.0; 99% confidence interval, 1.2-3.2) was higher among subjects with higher ASPECTS. CONCLUSIONS: ASPECTS is a strong predictor of outcome and a predictor of reperfusion. ASPECTS did not identify a subpopulation of subjects that particularly benefitted from endovascular therapy immediately after routine intravenous tPA. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: R von Kummer; K L Allen; R Holle; L Bozzao; S Bastianello; C Manelfe; E Bluhmki; P Ringleb; D H Meier; W Hacke Journal: Radiology Date: 1997-11 Impact factor: 11.105
Authors: Simerpreet Bal; Rohit Bhatia; Bijoy K Menon; Nandavar Shobha; Volker Puetz; Imanuel Dzialowski; Jayesh Modi; Mayank Goyal; Michael D Hill; Eric E Smith; Andrew M Demchuk Journal: Int J Stroke Date: 2012-09-13 Impact factor: 5.266
Authors: Andrew M Demchuk; Michael D Hill; Philip A Barber; Brian Silver; Suresh C Patel; Steven R Levine Journal: Stroke Date: 2005-09-15 Impact factor: 7.914
Authors: P A Barber; M D Hill; M Eliasziw; A M Demchuk; J H W Pexman; M E Hudon; A Tomanek; R Frayne; A M Buchan Journal: J Neurol Neurosurg Psychiatry Date: 2005-11 Impact factor: 10.154
Authors: Michael D Hill; Howard A Rowley; Felix Adler; Michael Eliasziw; Anthony Furlan; Randall T Higashida; Lawrence R Wechsler; Heidi C Roberts; William P Dillon; Nancy J Fischbein; Carolyn M Firszt; Gregory A Schulz; Alastair M Buchan Journal: Stroke Date: 2003-07-03 Impact factor: 7.914
Authors: Imanuel Dzialowski; Michael D Hill; Shelagh B Coutts; Andrew M Demchuk; David M Kent; Olaf Wunderlich; Rüdiger von Kummer Journal: Stroke Date: 2006-02-23 Impact factor: 7.914
Authors: Jens Fiehler; Christophe Cognard; Mauro Gallitelli; Olav Jansen; Adam Kobayashi; Heinrich P Mattle; Keith W Muir; Mikael Mazighi; Karl Schaller; Peter D Schellinger Journal: Eur Stroke J Date: 2016-07-26
Authors: Joseph P Broderick; Olvert A Berkhemer; Yuko Y Palesch; Diederik W J Dippel; Lydia D Foster; Yvo B W E M Roos; Aad van der Lugt; Thomas A Tomsick; Charles B L M Majoie; Wim H van Zwam; Andrew M Demchuk; Robert J van Oostenbrugge; Pooja Khatri; Hester F Lingsma; Michael D Hill; Bob Roozenbeek; Edward C Jauch; Tudor G Jovin; Bernard Yan; Rüdiger von Kummer; Carlos A Molina; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig S Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Kit N Simpson Journal: Stroke Date: 2015-10-20 Impact factor: 7.914
Authors: Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch Journal: J Biopharm Stat Date: 2018-07-09 Impact factor: 1.051
Authors: Zhong-Song Shi; David S Liebeskind; Bin Xiang; Sijian Grace Ge; Lei Feng; Gregory W Albers; Ronald Budzik; Thomas Devlin; Rishi Gupta; Olav Jansen; Tudor G Jovin; Monika Killer-Oberpfalzer; Helmi L Lutsep; Juan Macho; Raul G Nogueira; Marilyn Rymer; Wade S Smith; Nils Wahlgren; Gary R Duckwiler Journal: Stroke Date: 2014-05-29 Impact factor: 7.914
Authors: Ronen R Leker; Asaf Honig; Andrei Filioglo; Naaem Simaan; John M Gomori; Jose E Cohen Journal: Neuroradiology Date: 2020-10-06 Impact factor: 2.804
Authors: Robin Lemmens; Scott A Hamilton; David S Liebeskind; Tom A Tomsick; Andrew M Demchuk; Raul G Nogueira; Michael P Marks; Reza Jahan; Jan Gralla; Albert J Yoo; Sharon D Yeatts; Yuko Y Palesch; Jeffrey L Saver; Vitor M Pereira; Joseph P Broderick; Gregory W Albers; Maarten G Lansberg Journal: Neurology Date: 2016-01-22 Impact factor: 9.910
Authors: Ali Reza Noorian; Srikant Rangaraju; Chung-Huan Sun; Kumiko Owada; Fadi Nahab; Samir R Belagaje; Aaron M Anderson; Michael R Frankel; Raul G Nogueira Journal: Interv Neurol Date: 2015-09-18